NCT07275242

A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor

An Open-Label, Multi-site Phase I Clinical Study of SHR-A1811(sc) Subcutaneous Injection: Evaluating Pharmacokinetics, Safety, Tolerability, and Efficacy in Patients With Solid Tumor

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 107 (estimated)
• Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study is being conducted to evaluate the pharmacokinetics , safety, tolerability and efficacy in patients with solid tumor.

Conditions

• Solid Tumor

Interventions

Type	Name	Description
DRUG	SHR-A1811 Subcutaneous Injection	SHR-A1811 subcutaneous injection.
DRUG	SHR-A1811 for Injection	SHR-A1811 for injection.

Timeline

• Start date: 2025-12-23
• Primary completion: 2027-06-01
• Completion: 2027-12-01
• First posted: 2025-12-10
• Last updated: 2026-01-15

Locations

1 site across 1 country: China